Swedish Orphan Biovitrum AB (publ) : Consistent Growth, Surprisingly Affordable Valuation
SOBI, still valued at less than 20 times its expected profit for 2019 - a valuation that is surprisingly affordable in a market that is this expensive - remains one of the most promising European pharmaceutical companies.